Bradycardia associated with antithymocyte globulin treatment of a pediatric patient with sickle cell disease: a case report and literature review

Elazhary, Salwa; Alawyat, Hanaa Al

doi:10.1016/j.htct.2020.08.018

Cited by 6 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bradycardia is an uncommon cardiotoxic sequelae of ATG, with current data limited to some case reports and one series. 1 We suggested admission with cardiac monitoring during the next ATG cycle.…”

Section: Case 1: Bradycardia With Antithymocyte Globulinmentioning

confidence: 99%

Bradyarrhythmias in Cardio-Oncology

Fonseca

Cheng

et al. 2021

South Asian J Cancer

View full text Add to dashboard Cite

The relationship between bradyarrhythmias and cancer therapies has not been well described but is increasingly recognized. There have been extensive advances in oncological pharmacotherapy, with several new classes of drugs available including targeted agents, immune checkpoint inhibitors and CAR T cell therapy. This increasing repertoire of available drugs has revolutionized overall prognosis and survival of cancer patients but the true extent of their cardiovascular toxicity is only beginning to be understood. Previous studies and published reviews have traditionally focused on conventional chemotherapies and in arrhythmias in general, particularly tachyarrhythmias. The number of patients with both cancer and cardiovascular problems is increasing globally and oncologists and cardiologists need to be adept at managing arrythmia based scenarios. Greater collaboration between the two specialties including studies with prospective data collection in Cardio-Oncology are much needed to fill in knowledge gaps in this arena. This case-based review summarizes current available evidence of cancer treatment-related bradyarrhythmia incidence (including its different subtypes), possible mechanisms and outcomes. Furthermore, we propose a stepwise surveillance and management protocol for patients with suspected bradyarrhythmia related to cancer treatment.

show abstract

Section: Case 1: Bradycardia With Antithymocyte Globulinmentioning

confidence: 99%